Jordana Kron

Jordana Kron

Auto-generated profile, based on publicly available information

Jordana Kron

Virginia Commonwealth University, Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Richmond, Virginia, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2019 in Current Cardiology Reports
Verified
Journal Article
Closed access
PDF file
PMPranav Mankad
Pranav Mankad
BMBrian Mitchell
Brian Mitchell
DBDavid Birnie
David Birnie
JKJordana Kron
Jordana Kron

8 November 2021 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
JKJordana Kron
Jordana Kron
TCThomas Crawford
Thomas Crawford
VMVirginia Mihalick
Virginia Mihalick
FBFrank Bogun
Frank Bogun
JJJennifer H. Jordan
Jennifer H. Jordan
AAAntonio Abbate
Antonio Abbate
Background: Sarcoidosis is an inflammatory disease characterized by the formation of granulomas, which involve the heart in up to 25% of patients. Cardiac sarcoidosis can lead to life threatening arrhythmias and heart failure. While corticosteroids have been used as a treatment for over 50 years, they are associated with hypertension, diabetes, and weight gain, further increasing cardiovascular risk. Interleukin-1 (IL-1) is the prototypical proinflammatory cytokine that works to activate the nuclear transcription factor NF-kB, one of the targets of glucocorticoids. IL-1 also plays an important role also in the pathophysiology of heart disease including atherosclerosis, myocardial infarction, and myocarditis.Methods: Building on a network of research collaborators developed in the Cardiac Sarcoidosis Consortium, we will investigate the feasibility and tolerability of treatment of CS with anakinra at two National Institute of Health Clinical and Translational Science Award (CTSA) hubs with expertise in cardiac sarcoidosis. In this pilot study, up to 28 patients with cardiac sarcoidosis will be recruited to compare the administration of an IL-1 blocker, anakinra, 100 mg daily on top of standard of care versus standard of care only for 28 days and followed for 180 days. Utilizing surrogate endpoints of changes in systemic inflammatory biomarkers and cardiac imaging, we aim to determine whether IL-1 blockade with anakinra can combat systemic and cardiac inflammation in patients with cardiac sarcoidosis.Discussion: The current trial demonstrates an innovative collaborative approach to clinical trial development in a rare, understudied disease that disproportionately affects females and minorities.Trial RegistrationThe trial was registered prospectively with ClinicalTrials.gov on July 12, 2019, identifier NCT04017936.

1 September 2019 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
JKJordana Kron
Jordana Kron
AMAdolfo Gabriele Mauro
Adolfo Gabriele Mauro
ABAldo Bonaventura
Aldo Bonaventura
STStefano Toldo
Stefano Toldo
FSFadi N. Salloum
Fadi N. Salloum
AAAntonio Abbate
Antonio Abbate

16 February 2021 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
LRLynda E. Rosenfeld
Lynda E. Rosenfeld
MCMina K. Chung
Mina K. Chung
CHClifford V. Harding
Clifford V. Harding
PSPaolo Spagnolo
Paolo Spagnolo
JGJohan Grunewald
Johan Grunewald
JEJerry D. Estep
Jerry D. Estep
Cardiac sarcoidosis is a component of an often multiorgan granulomatous disease of still uncertain cause. It is being recognized with increasing frequency, mainly as the result of heightened awareness and new diagnostic tests, specifically cardiac magnetic resonance imaging and 18 F-fluorodeoxyglucose positron emission tomography scans. The purpose of this case-based review is to highlight the potentially life-saving importance of making the early diagnosis of cardiac sarcoidosis using these new tools and to provide a framework for the optimal care of patients with this disease. We will review disease mechanisms as currently understood, associated arrhythmias including conduction abnormalities, and atrial and ventricular tachyarrhythmias, guideline-directed diagnostic criteria, screening of patients with extracardiac sarcoidosis, and the use of pacemakers and defibrillators in this setting. Treatment options, including those related to heart failure, and those which may help clarify disease mechanisms are included.

1 December 2022 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
JPJonathan P. Piccini
Jonathan P. Piccini
AUAndrea M Cooper Medical School of Rowan University
Andrea M Cooper Medical School of Rowan University
PSParikshit Sharma
Parikshit Sharma
JKJordana Kron
Jordana Kron
WTWendy Tzou
Wendy Tzou
PWPaul J. Wang
Paul J. Wang
Despite the global COVID-19 pandemic, during the past 2 years, there have been numerous advances in our understanding of arrhythmia mechanisms and diagnosis and in new therapies. We increased our understanding of risk factors and mechanisms of atrial arrhythmias, the prediction of atrial arrhythmias, response to treatment, and outcomes using machine learning and artificial intelligence. There have been new technologies and techniques for atrial fibrillation ablation, including pulsed field ablation. There have been new randomized trials in atrial fibrillation ablation, giving insight about rhythm control, and long-term outcomes. There have been advances in our understanding of treatment of inherited disorders such as catecholaminergic polymorphic ventricular tachycardia. We have gained new insights into the recurrence of ventricular arrhythmias in the setting of various conditions such as myocarditis and inherited cardiomyopathic disorders. Novel computational approaches may help predict occurrence of ventricular arrhythmias and localize arrhythmias to guide ablation. There are further advances in our understanding of noninvasive radiotherapy. We have increased our understanding of the role of His bundle pacing and left bundle branch area pacing to maintain synchronous ventricular activation. There have also been significant advances in the defibrillators, cardiac resynchronization therapy, remote monitoring, and infection prevention. There have been advances in our understanding of the pathways and mechanisms involved in atrial and ventricular arrhythmogenesis.

16 July 2019 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
SGSampath Gunda
Sampath Gunda
DADaniel Akyeampong
Daniel Akyeampong
JGJose Gomez‐Arroyo
Jose Gomez‐Arroyo
DJDaniel G. Jovin
Daniel G. Jovin
NKNarayan G. Kowlgi
Narayan G. Kowlgi
JHJose F. Huizar
Jose F. Huizar